Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation

Luca Laurenti, Simona Sica, Maria Antonietta Blasi, Laura De Padua, Remo Battendieri, Michela Tarnani, Giancarlo Savino, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

18 Citazioni (Scopus)

Abstract

B-cell lymphomas constitute the most frequent malignant neoplasm of the ocular adnexal, often presenting with localized disease. Five patients with primary localized CD20 positive B cell non Hodgkin ocular adnexal lymphomas received intralesional rituximab at the dose of 5mg once a week for one month, followed by 10mg weekly in case of incomplete response. Four of five patients obtained regression of symptoms and 2 of them showed complete response. No patients experienced side effects besides pain on the site of the injection. Local treatment with Rituximab for OAL is a safe and useful first-line therapeutic option.
Lingua originaleEnglish
pagine (da-a)682-684
Numero di pagine3
RivistaLeukemia Research
Volume35
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Aged
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Female
  • Humans
  • Injections, Intralesional
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Orbital Neoplasms
  • Pilot Projects
  • Remission Induction
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation'. Insieme formano una fingerprint unica.

Cita questo